More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Subscribe To Our Newsletter & Stay Updated
